AstraZeneca’s Covid-19 vaccine has had a bumpy ride, but the prominent drugmaker is ready to start supplying their shots to COVAX.

The first doses of the AstraZeneca/Oxford vaccine were shipped to Ghana and Cote D’Ivoire, AstraZeneca announced Tuesday, with more set to begin arriving this week in the Philippines, Indonesia, Fiji, Mongolia and Moldova. For many of these countries, these doses represent their first Covid-10 vaccines, AstraZeneca said.

The US could have a third authorized Covid-19 vaccine within hours.

The FDA’s advisory committee voted unanimously — 22-0 — to recommend the agency issue an emergency use authorization for J&J’s vaccine. If they follow the precedent of the Pfizer and Moderna vaccine, the FDA will likely authorize the vaccine by Saturday, immediately adding a few million doses to the US supply and adding a 100 million by June. An authorization would give the world its first single-dose vaccine, a major weapon in the effort to vaccinate the world and bring the virus to heel, particularly in rural and developing areas.

Despite having already received an emergency use authorization for its Covid-19 antibody in non-hospitalized patients last November, Regeneron continued to conduct trials to evaluate the cocktail’s effectiveness. Now, the big biotech has received some good news from their IDMC.

On the IDMC’s recommendation, Regeneron will be shutting down enrollment in the placebo group of a Phase III outpatient trial for their REGN-COV program — a mix of casirivimab with imdevimab — after investigators found “clear clinical efficacy” in both doses compared to the control, the company announced Thursday. CSO George Yancopoulos also said in a statement that the cocktail can neutralize emerging strains of the novel coronavirus.

The first real-world evidence for Pfizer/BioNTech’s Covid-19 vaccine is in, and there’s a lot for the companies to like.

Two months into the vaccine’s rollout in Israel, researchers from the country’s Clalit Research Institute have published the first study to be peer-reviewed over whether or not the shot is effective outside a controlled clinical trial setting. They have found the two-dose vaccine regimen cut symptomatic Covid-19 cases by 94% across all age groups and severe cases by almost as much.

In the search for a better Covid-19 therapeutic, GlaxoSmithKline and Vir have partnered up on two antibodies they hope have a chance. GSK is also testing its own in-house antibody, and early results may have shut the door on its widespread use.

A combination of GSK’s monoclonal antibody otilimab plus standard of care couldn’t best standard of care alone in preventing death and respiratory failure in hospitalized Covid-19 patients after 28 days, according to data from the Phase IIa OSCAR study unveiled Thursday.

CanSino says their single-dose Covid-19 vaccine is 65.28% effective at preventing symptomatic Covid-19 cases, and they’ve officially filed for authorization with China’s National Medical Products Administration.

The vaccine was 90.07% effective at preventing severe disease 28 days after the single dose, according to a statement reported by local media. Efficacy rates were slightly higher 14 days after the single dose, at 68.83% for symptomatic disease and  95.47% for severe disease.

NeuroRx’s Covid-19 treatment was already shot down by the FDA once, and it failed the primary endpoint in a Phase IIb/III readout — but that won’t stop CEO Jonathan Javitt from lining up a Hail Mary pass to regulators.

Javitt gave Endpoints News a preview of Phase IIb/III data based on an initial 28-day endpoint on Monday afternoon. At 28 days, critically ill Covid-19 patients given NeuroRx and Relief Therapeutics’ aviptadil were 35% more likely to recover and be discharged from the hospital compared to those on a placebo, Javitt said. However, the p-value was 0.08 — falling well below the 0.05 p-value needed to demonstrate statistical significance, meaning there’s a greater chance that the results were random and not tied to the treatment.

Pfizer and Moderna are on track to deliver a combined 220 million doses of their mRNA vaccines in the US by the end of March, the companies told a congressional committee, setting them up to offer enough shots to vaccinate 300 million Americans by the end of July — a goal President Joe Biden has outlined in recent days.

Previously, supply wasn’t supposed to reach that level until September.

Both drugmakers say the new goal reflects significant expansions in their manufacturing capacity. And J&J said it could come in with millions of its one-shot vaccine if the FDA authorizes that third option following an adcomm scheduled later this week.